Tioga Pharmaceuticals is focused on developing novel treatments for gastrointestinal diseases, primarily advancing the compound asimadoline for diarrhea-predominant irritable bowel syndrome (D-IBS). The company is conducting a 600-subject, randomized, double-blind, placebo-controlled Phase 3 trial under a special protocol assessment (SPA) with the U.S. FDA. That trial is one of two registration trials required for U.S. approval, and asimadoline has been granted Fast Track designation by the FDA for D-IBS. In September 2009, Ono Pharmaceutical licensed exclusive rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan, while Tioga retains all other rights. The company is led by chairman and CEO Stuart Collinson, Ph.D. Tioga recently closed a Series B financing to support its clinical and development activities. Tioga Pharmaceuticals is focused on developing novel treatments for gastrointestinal diseases, with its lead asset asimadoline, an orally administered small molecule. The company is advancing asimadoline for patients with diarrhea-predominant irritable bowel syndrome (D-IBS). Tioga closed an $18M equity financing to support its clinical programs. Proceeds from the financing will fund a Phase 3 clinical trial of asimadoline. In September 2009 Ono Pharmaceutical licensed exclusive rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan, and plans to start clinical studies in Japan in the second quarter of 2010. Tioga retains all other rights to the compound.

Total raised

$28M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2012